Evidence map›Paper›PMID 39722169›Full record

ArticleInternational journal of dermatology2025

Unbiased Drug Target Prediction Reveals Sensitivity to Ferroptosis Inducers, HDAC and RTK Inhibitors in Melanoma Subtypes.

Indira Pla, Botond L Szabolcs, Petra Nikolett Péter, Zsuzsanna Ujfaludi, Yonghyo Kim, Peter Horvatovich, Aniel Sanchez, Krzysztof Pawlowski, Elisabet Wieslander, Magdalena Kuras and 26 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

36 authors.

Indira Pla *Department of Biomedical Engineering, Faculty of Engineering, LTH, Lund University, Lund, Sweden.ORCID https://orcid.org/0000-0002-0839-7829
Botond L Szabolcs *HCEMM-SU Translational Dermatology Research Group, Semmelweis University, Budapest, Hungary.ORCID https://orcid.org/0009-0002-5304-7032
Petra Nikolett Péter *HCEMM-SU Translational Dermatology Research Group, Semmelweis University, Budapest, Hungary.
Zsuzsanna UjfaludiDepartment of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Yonghyo KimDrug Discovery Platform Research Center, Therapeutics and Biotechnology Division, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea.
Peter HorvatovichGroningen Research Institute of Pharmacy, Analytical Biochemistry, University of Groningen, Groningen, The Netherlands.
Aniel SanchezSection for Clinical Chemistry, Department of Translational Medicine, Skåne University Hospital Malmö, Malmö, Sweden.
Krzysztof PawlowskiSection for Clinical Chemistry, Department of Translational Medicine, Skåne University Hospital Malmö, Malmö, Sweden.
Elisabet WieslanderSection for Clinical Chemistry, Department of Translational Medicine, Skåne University Hospital Malmö, Malmö, Sweden.
Magdalena KurasDepartment of Biomedical Engineering, Faculty of Engineering, LTH, Lund University, Lund, Sweden.
Jimmy Rodriguez MurilloThermo Fisher Scientific, Waltham, MA, USA.
Jéssica GuedesEuropean Cancer Moonshot Lund Center, Lund, Sweden.
Dorottya M P PálHCEMM-SU Translational Dermatology Research Group, Semmelweis University, Budapest, Hungary.ORCID https://orcid.org/0000-0002-9426-487X
Anna A AscsillánHCEMM-SU Translational Dermatology Research Group, Semmelweis University, Budapest, Hungary.
Lazaro Hiram BetancourtEuropean Cancer Moonshot Lund Center, Lund, Sweden.
István Balázs NémethDepartment of Dermatology and Allergology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Jeovanis GilEuropean Cancer Moonshot Lund Center, Lund, Sweden.ORCID https://orcid.org/0000-0003-3601-3893
Natália Pinto de AlmeidaEuropean Cancer Moonshot Lund Center, Lund, Sweden.
Beáta SzeitzDivision of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.ORCID https://orcid.org/0000-0001-6414-0537
Leticia SzadaiDepartment of Dermatology and Allergology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Viktória DomaDepartment of Dermatology and Allergology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Nicole WoldmarEuropean Cancer Moonshot Lund Center, Lund, Sweden.
Áron BarthaDepartment of Bioinformatics, Semmelweis University, Budapest, Hungary.
Zoltan PahiMTA-SE Lendület "Momentum" Dermatology Research Group, Hungarian Academy of Sciences and Semmelweis University, Budapest, Hungary.
Tibor PankotaiDepartment of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Balázs GyőrffyDivision of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.
A Marcell SzaszDivision of Oncology, Department of Internal Medicine and Oncology, Semmelweis University, Budapest, Hungary.
Gilberto DomontChemistry Institute Federal, University of Rio de Janeiro, Rio de Janeiro, Brazil.
Fábio NogueiraProteomics Unit, Institute of Chemistry and Research Center for Precision Medicine, Institute of Biophysics Carlos Chagas Filho, Federal Univesity of Rio de Janeiro, Rio de Janeiro, Brazil.
Ho Jeong KwonChemical Genomics Leader Research Laboratory, Department of Biotechnology, College of Life Science and Biotechnology, Yonsei University, Seoul, Korea.
Roger AppelqvistEuropean Cancer Moonshot Lund Center, Lund, Sweden.
Sarolta KárpátiDepartment of Dermatology, Venereology and Dermatooncology, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
David FenyöInstitute for Systems Genetics, NYU Grossman School of Medicine, New York, NY, USA.
Johan MalmSection for Clinical Chemistry, Department of Translational Medicine, Skåne University Hospital Malmö, Malmö, Sweden.
György Marko-Varga *European Cancer Moonshot Lund Center, Lund, Sweden.
Lajos V Kemény *HCEMM-SU Translational Dermatology Research Group, Semmelweis University, Budapest, Hungary.ORCID https://orcid.org/0000-0002-8233-1844

Funding

Proteogenomic Data Analysis for Cancer Systems Biology and Clinical TranslationU24CA210972 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI DING, LI, FENYO, DAVID · 2016 to 2020
$3.3M
EU's Horizon 2020 research and innovation program 739593Fru Berta Kamprads StiftelseHungarian Scientific Research Fund N-OTKA 114-460Hungarian Scientific Research Fund OTKA-125509Hungarian Scientific Research Fund OTKA FK138696Lendület "Momentum" grant from the Hungarian Academy of Sciences LP2024-12/2024NCI NIH HHS U24 CA210972NCI NIH HHS U24CA210972Semmelweis Egyetem STIA-KFI2021Swedish Pharmaceutical Society
6 · The paper itself

Abstract

backgroundThe utilization of PD1 and CTLA4 inhibitors has revolutionized the treatment of malignant melanoma (MM). However, resistance to targeted and immune-checkpoint-based therapies still poses a significant problem.

objectiveHere, we mine large-scale MM proteogenomic data to identify druggable targets and forecast treatment efficacy and resistance.

methodsLeveraging protein profiles from established MM subtypes and molecular structures of 82 cancer treatment drugs, we identified nine candidate hub proteins, mTOR, FYN, PIK3CB, EGFR, MAPK3, MAP4K1, MAP2K1, SRC, and AKT1, across five distinct MM subtypes. These proteins are potential drug targets applicable to one or multiple MM subtypes. Additionally, by integrating proteogenomic profiles obtained from MM subtypes with MM cell line dependency and drug sensitivity data, we identified a total of 162 potentially targetable genes. Lastly, we identified 20 compounds exhibiting potential drug impact in at least one melanoma subtype.

resultsEmploying these unbiased approaches, we have uncovered compounds targeting ferroptosis demonstrating a striking 30× fold difference in sensitivity among different subtypes.

conclusionsOur results suggest innovative and novel therapeutic strategies by stratifying melanoma samples through proteomic profiling, offering a spectrum of novel therapeutic interventions and prospects for combination therapy.

Indexed as

Antineoplastic AgentsFerroptosisHistone Deacetylase InhibitorsMelanomaProtein Kinase InhibitorsSkin NeoplasmsCell Line, TumorDrug Resistance, NeoplasmHumansMolecular Targeted TherapyProteomicsAntineoplastic AgentsHistone Deacetylase InhibitorsProtein Kinase Inhibitorsdrug target predictionferroptosisHDACmalignant melanomaRTK inhibitorskin cancer

Identifiers

PMID39722169
PMCPMC12008611

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.